Get started

Biotech

Looking for a long term entry into Globus MedicalI’m looking for a long term investment in a sea of overvalued bio & tech companies. Globus Medical caught my eye as a potential candidate after a large dark pool sell and recent pullback in indexes Globus Medical's index membership is Russell 1000, Russell 3000 and S&P Midcap 400. Financial Observations: PE ratio of 37 a return to 2017 levels. 7B Market Cap Consistent Year over Year revenue growth. Nominal Debt Exceeds earnings expectations Steady asset growth Regular employment growth Personal Experience A surgical clinic I do marketing and websites for recently added one of the Globus Medical robot arm surgical assistants. The chief surgeon told me his surgery averages went from 1hr to 10m. The client has also made it a priority for us to increase marketing spend and patient intake support to increase daily surgery capacity. I’m curious to know what the more seasoned investors think of GMED and if this is a good time to make an entry for a long term holding. Not Financial Advice. Just my own Personal Investment Due Diligence.
NYSE:GMEDLong
by SPYvsGME
1
$Enzc where do we go from here??? The chart broke down from our previous wedge, causing a wide broadening formation. We broke below the 0.618 fib level, would have liked to see a sustained volume shelf there creating a better support. Price will need to bounce from 0.1011 and close above that level or we will continue to see continued selling pressure. EXPECT ALOT OF VOLATILITY FOR THE REMAINDER OF DECEMBER! I still haven't sold a single share and will continue to aquire more every chance I get (seems more now than ever) Know your 50/30/20 rule! 50% of what a stock does is determined by what the overall market does 30% of what a stock does is determined by what the sector & industry group does 20% of the movement of the stock is determined by the analysis of the stock itself
OTC:ENZC
by OptionStonker
Record financials warrant a re-ratingQ3 2021 results warrant a re-rating of this $30M mkt cap biotech play: - Revenue was $25.3 million in the third quarter of 2021, up 575%, compared to $3.7 million over the prior three-month period ending June 30, 2021. - Gross profit was $10.5 million in the third quarter of 2021, up 1,288%, compared to $753,535 over the prior three-month period ending June 30, 2021. - Net income was $6.8 million in the third quarter of 2021, compared to a net loss of $8.7 million over the prior three-month period ending June 30, 2021.
MLong
by wealth_bakery
3
$BFRI entry PT 6 Target PT 11-20 and higherNote: ER 11/30 Tues Roth Capital analyst Jonathan Aschoff initiated coverage of BFRI stock with a buy rating and $20 price target. The analyst believes the stock is poised for growth thanks to its U.S. sales plans. Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
NASDAQ:BFRILong
by BADQOMOCAWGOWLD
$LGVN entry PT 25 Target PTs 43-49 and higherLongeveron stock is up by a multiple of 11 after the FDA gave a Rare Pediatric Disease designation for a heart medication last week. Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
NASDAQ:LGVNLong
by BADQOMOCAWGOWLD
1
$ISPC entry 14.65-16.15-ish Target PTs 29 and higheriSpecimen, Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables researchers to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
ILong
by BADQOMOCAWGOWLD
1
Big Pharma Holds the LineLast week ended with sell-offs amid fears about the new extremely contagious COVID 19 Omicron variant. Crude and stock markets suffered. But during this brief rally some shares continued to gain, and it is no wonder that these are the stocks of vaccine producers. Pfizer stocks posted a new all-time high on Friday rising by 6.11% to $54.94. Stocks were additionally supported when the company promised to develop a tailor-made vaccine in 100 days if the Omicron variant cannot be tamed by the current vaccine. The shares also reacted to the news that the European Medicines Agency approved the BioNTech-Pfizer vaccine for children aged 5-11. That is good news for the world’s top-selling medicine of the year. In order for the shares to continue on this upside climb, the price of Pfizer stocks need to remain above $50.49, which is the shares’ peak which was reached in August, and also keep with its upward trend that started on November 4 and has a support level at $51.50-51.80. BioNTech stocks also performed well, adding some 14.19% on Friday. The technical picture suggests stocks may rise further as they managed to break through the downward channel they have been on since August 10. Besides, we may see a reverse pattern “double dip” with a neck level crossing $304.35. The implementation of this pattern may boost stock prices to $378.67-401.19. Stock prices are close to the 61.8% Fibonacci correction level of the lows of August-November at $365.13. In case this landmark is passed, investors will have more reasons to push the stock to this year’s highs. Moderna stocks also enjoyed the sunny side of the COVID-19 panic as they soared by 20.57% to $329.63 on Friday, breaking from their downward channel which began on September 23. The next price target is at the $387-395 area, where the 61.8% Fibonacci level from the downside correction of August-November, and the resistance line of the downward trend from August 10 are located. I have already said that all Big Pharma stocks should be included in portfolios as they may all rally. Nevertheless, at the beginning of the new week fears around the South African Omicron variant have faded as the virologist Barry Schoub, who advises the South African government, said he did not believe the variant will lead to a major new wave of serious illness and the vaccine will still protect most people from severe cases of COVID-19. But the overall picture now that there is a new variant in circulation is unclear, and the market may become agitated. In this case the best option is to have downside-resistant stocks in your portfolio. Some people may find profit anywhere!
NASDAQ:MRNALong
by scavoanastasiia
$BFRIBiofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
NASDAQ:BFRILong
by BADQOMOCAWGOWLD
$MRNAModerna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by BADQOMOCAWGOWLD
$APVOAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
NASDAQ:APVOLong
by BADQOMOCAWGOWLD
1
$QLGNQualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.
NASDAQ:QLGNLong
by BADQOMOCAWGOWLD
4
🔴 Analysis of biotech with great potentialIn this post I analyzed one interesting biotech Endo International. Endo is a global pharmaceutical corporation headquartered in Dublin (legal) and Malvern, PA (operating). It was created in 1997 on a joint basis with DuPont Merck. Among the areas of drug development: immunotherapy, dermatology, infectious diseases, insomnia, orthopedics, urology, cellulite, oncology, endocrinology. The company also manufactures pain relievers and equipment needed to diagnose various diseases. Revenue for 2020 is $ 2.9 billion, profit is $ 0.25 million. Capitalization is $ 1.4 billion. Employees 3172. The company's business is represented by 4 areas: 1. Endo Pharmaceuticals develops unique products from scratch. At the moment, this direction has 16 commercial drugs. There are only 2 drugs in development. 2. Par Pharmaceuticals produces generic (copies) pharmaceuticals. This company was acquired by the American company Endo Pharmaceuticals in 2015 for $ 8.05 billion. This deal allowed Endo to become one of the five largest manufacturers of generics in the United States. Par Pharmaceuticals manufactures about 140 drugs. 3. Endo Aesthetics develops solutions for the treatment of cellulite. 4. Paladin Labs specializes in the acquisition and licensing of new pharmaceutical products for the Canadian market, and also manufactures products for the treatment of allergies, urological and dermatological diseases, diseases of the central nervous system and women's health. The company was acquired by Endo Pharmaceuticals in 2013 for $ 1.6 billion to gain access to the Canadian market and expand into emerging markets. Endo reached its peak value in 2015, then $ 90 was given per share. This was followed by a collapse in prices amid accusations of the "opioid epidemic" that began in the United States in the late 90s and lasted until 2016. This term refers to a large number of abuse and fatal overdoses of drugs that contain opiates. Authorities estimate that more than 450,000 Americans have died from opioids in 17 years. Purdue Pharma was identified as the main culprit. However, lawsuits were brought against other corporations as well. Endo has been identified as one of the culprits in the epidemic in 3 states: Ohio, Missouri and Mississippi. In 2016, most of the company's revenues were generated precisely from the sale of opioid-based painkillers. On November 2, an Orange County Supreme Court judge issued a preliminary ruling that relieves the company of responsibility for fueling the opioid epidemic in the United States. On this day, quotes added almost 10%. In 2020, Endo, for the first time in many years, made a profit of $ 184 million. Prior to that, for several years in a row, it managed to reduce losses, which in 2017 exceeded $ 2 billion. In general, the company's revenue is stagnating, the company is teetering on the brink of break-even. An interesting fact: the company for 30 quarters in a row manages to show financial indicators better than analysts' forecasts (in the pharmaceutical industry this is rarely seen). On November 4, the report for the third quarter was released. The published figures significantly exceeded analysts' estimates. On November 5, quotes added 25%. 🔧In terms of technique, the graph looks towards the short: 1) The price approached a strong weekly level. 2) Closing of the daily and weekly candles near the level and under the very LOW. 3) The price has broken the local level of $ 6.24 4) There is a large power reserve at the bottom. 5) Pulling the local maximum to the level, they are not allowed to go up. 6) Accumulation before the level. 7) Parabolic rounding. 8) Recoilless movement over 250%. Breakout of the local level $ 6.14 The price is likely to consolidate in the $ 6.15 - $ 6.50 channel with false breakouts of the support level before starting a correction. Be careful. Goal 1: $ 5.3 Target 2 (risk): $ 3.5 (more than 40% of the movement) NOT IRR.
EShort
by Trader_Ivankov
2
$PROGProgenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
PLong
by BADQOMOCAWGOWLD
$LGVNLongeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
NASDAQ:LGVNLong
by BADQOMOCAWGOWLD
3
$KZR Long term PT 35 and higherKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
NASDAQ:KZRLong
by BADQOMOCAWGOWLD
$MIRM november update*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Recap: My team entered $MIRM on 10/29/21 at $15.70 per share. Our first take profit is at $26. Mirum Pharmaceuticals $MIRM released their 3rd quarter earnings today after market close. In this report they announced a loss of -$1.55 per share on revenue of $5.0 million. This earnings beat is staggering, especially when acknowledging the fact that the revenue consensus was only $0.8 million. $MIRM is still an under the radar company currently, but a revenue beat of 502.4% will definitely turn some heads. In addition, post-earnings five insiders accumulated a vast amount of shares. These insiders know what's coming, and lucky for us we do too. Our first take profit is honestly a huge underestimate of this companies potential, and in the future we may have to make some major adjustments. This is a buy and throw away the key type of investment. My teams holding! Will you? OUR ENTRY: $15.70 FIRST TAKE PROFIT: $26 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
4
Possibly the most undervalued stock on the TSX!- $19M mkt cap / 11M float - $28.4M cash eq. - $17.1M Q3 revenue / $7M adjusted EBITDA - Options at $3.27 - Warrants at $3.53 - Enterprise value (as of Sep 30, 2021): $103.8M!! - Canadian Commercial business is focused on Pain, Neurology, Allergy, And Dermatology therapeutics. - 17 Global Distribution Partners across 31 Countries. - Over 100 global patents and patent applications - 20+ products, 7 proprietary products, ~ 100 employees
MLong
by wealth_bakery
TARGET HIT $PFR 9.05% in 14 days TARGET HIT $PFR 9.05% in 14 days Wooo hoooo…. Great game!!! Definitely room for this to go higher... —————— I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Check out my ideas, but also do your own due diligence. If you want me to analyze any stock or ETF just leave me a comment and I’ll do it if I can. Have fun, y’all!! (\_/) ( •_•) / >🚀
NYSE:PFE
by SPYder_QQQueen_Trading